Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Line Development Market

Cell Line Development Market Share

Report ID: GMI429
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Cell Line Development Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical & biotechnology companies that manufacture cell line development products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for cell line development.

Cell Line Development Market Companies

Prominent players operating in the cell line development industry are as mentioned below:

Advanced Instruments, LLC
Aragen Life Sciences Ltd.
ASIMOV
Cytiva (Danaher Corporation)
Eurofins Scientific
Fyonibio
GensSript Biotech
Lonza Group AG
Novartis AG
ProBioGen
PromoCell
Sartorius AG
Sigma Aldrich (Merck KGaA)
Thermo Fisher Scientific Inc.
WuXi AppTec

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The cell line development market was valued at USD 5.8 billion in 2023 and will grow at 10.3% CAGR during 2024-2032, driven by the global prevalence of cancer owing to adoption of sedentary lifestyles.

The reagents & media segment of the market recorded USD 2.6 billion in 2023 and will grow through 2032, driven by recurring demand for media and reagents during the cell line development process.

North America cell line development market secured 34.3% share in 2023 and will expand rapidly through 2032, driven by huge patient base prone to infectious and chronic diseases.

Advanced Instruments, LLC, Aragen Life Sciences Ltd., ASIMOV, Cytiva (Danaher Corporation), Eurofins Scientific, Fyonibio, GensSript Biotech, and Lonza Group AG among others.